

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A

For that derivative,-

N/A

Parties to the derivative:

N/A

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Two

Details of transactions requiring disclosure-

Date of transaction:

30-Aug-18

Nature of transaction:

Transaction one:
6,505,957 ordinary units were issued to NorthWest Healthcare Properties Management Limited, manager of Vital Healthcare Property Trust, as consideration for the manager's incentive fee in accordance with clauses 22.2(b) and 22.3(b) of the Trust Deed.

Transaction two: immediately upon the issue of units under transaction one, 4,100,000 units were transferred to Craigs Investment Partners Limited on behalf of certain of its third party clients.

Transactions one and two completed simulatenously such that the 4,100,000 units transferred pursuant to transaction two were, in fact, issued directly to Craigs Investment Partners Limited and were never held by NorthWest Healthcare Properties Management Limited.

Name of any other party or parties to the transaction (if known):

Craigs Investment Partners Limited & Forsyth Barr Limited

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

The 6,505,957 units were issued as consideration for NorthWest Healthcare Properties Management Limited's management incentive fee in accordance with clauses 22.2(b) and 22.3(b) of the Trust Deed. The consideration received for the contemporaneous disposal of 4,100,000 units was \$2.055 per unit.

Number of financial products to which the transaction related:

Transaction one: 6,505,957
Transaction two: (4,100,000)

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

N/A

Date of the prior written clearance (if any):

N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

ordinary units

Nature of relevant interest:

Paul Dalla Lana has a relevant interest in:
(a) 102,684,228 ordinary units held by NWI Healthcare Properties LP (as beneficial owner); and
(b) 8,139,064 ordinary units held by NWI NZ Management Company Limited (as beneficial owner).

For that relevant interest,-
Number held in class:
Current registered holder(s):

110,823,292
Deutsche Securities Australia Limited (105,977,178) and Forsyth Barr Custodians Limited (4,846,114)

For a derivative relevant interest,-
Type of derivative:


N/A

Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:


September 3, 2018

or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: